Want to see HK:1666 full AI Analyst Report?
Tong Ren Tang Technologies Co (1666) AI Stock Analysis
Top Page
Tong Ren Tang Technologies Co
(HKEX:1666)
The score is primarily driven by mixed financial performance: a solid balance sheet and a sharp 2025 cash-flow rebound are tempered by weakening 2025 revenue and profitability and cash-flow volatility. Valuation is a key positive (low P/E and high dividend yield), while technicals are neutral-to-soft with price below longer-term moving averages.
Tong Ren Tang Technologies Co (1666) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 511.29M
- Dividend Yield
- 6.93%
- Average Volume (3M)
- 1.42M
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- 0.61
- Revenue Growth
- -13.93%
- EPS Growth
- -25.30%
- Country
- Hong Kong
- Employees
- 3,801
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Tong Ren Tang Technologies Co Business Overview & Revenue Model
Company Description
Tong Ren Tang Technologies Co. Ltd., a company founded in 1669 and based in Beijing, People's Republic of China, maintains extensive operations across Mainland China and Hong Kong. Its primary activities center on the manufacturing and sale of tradit...
How the Company Makes Money
The company makes money primarily by selling traditional Chinese medicine and related healthcare products. Its core revenue stream is product sales, which typically include (1) manufactured TCM pharmaceutical products (e.g., proprietary Chinese medic...
Tong Ren Tang Technologies Co Financial Statement Overview
Summary
Financials are mixed. Income statement trends weakened in 2025 with revenue down (-9.1%), margin compression, and lower net income, which weighs on the score. Offsetting this, the balance sheet looks relatively solid with moderate and improving leverage (debt-to-equity ~0.30) and growing equity. Cash flow rebounded strongly in 2025 (OCF ~1.56bn; FCF ~1.45bn) but remains volatile after a very weak 2024, limiting confidence.
Income Statement
58NeutralBalance Sheet
74PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.77B | 6.48B | 7.26B | 6.77B | 5.99B | 5.40B |
| Gross Profit | 2.13B | 2.47B | 2.88B | 2.85B | 2.59B | 2.29B |
| EBITDA | 991.37M | 1.14B | 1.27B | 1.39B | 1.47B | 1.33B |
| Net Income | 306.75M | 396.28M | 521.79M | 590.19M | 582.89M | 507.25M |
Balance Sheet | ||||||
| Total Assets | 13.35B | 13.72B | 14.41B | 13.51B | 12.48B | 11.59B |
| Cash, Cash Equivalents and Short-Term Investments | 5.00B | 4.84B | 4.38B | 4.24B | 4.18B | 3.89B |
| Total Debt | 1.91B | 2.17B | 2.43B | 1.63B | 1.59B | 1.64B |
| Total Liabilities | 3.30B | 3.34B | 4.24B | 3.86B | 3.47B | 3.44B |
| Stockholders Equity | 7.30B | 7.34B | 7.21B | 6.89B | 6.48B | 5.98B |
Cash Flow | ||||||
| Free Cash Flow | 1.15B | 1.45B | -158.56M | 450.78M | 565.85M | 877.01M |
| Operating Cash Flow | 1.25B | 1.56B | 15.61M | 554.17M | 723.77M | 1.03B |
| Investing Cash Flow | -11.46M | 50.30M | 1.05B | -1.07B | 43.01M | -197.36M |
| Financing Cash Flow | -1.15B | -1.01B | 288.35M | -497.76M | -499.45M | -474.67M |
Tong Ren Tang Technologies Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1666, the sentiment is Negative. The current price of 2.98 is below the 20-day moving average (MA) of 3.04, below the 50-day MA of 3.11, and below the 200-day MA of 3.54, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.03 is Neutral, neither overbought nor oversold. The STOCH value of 23.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1666.
Tong Ren Tang Technologies Co Peers Comparison
Overall Rating
HK:023977Outperform
HK:361372Outperform
HK:109365Neutral- HK:166664Neutral
HK:089758.6Neutral
HK:057052.75Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 77Outperform | HKD 774.43M | 7.76 | 13.59% | 7.44% | 10.63% | 39.44% |
| HK:3613 | 72Outperform | HKD 4.73B | 10.23 | 11.15% | 6.55% | -20.79% | -30.04% |
| HK:1093 | 65Neutral | HKD 90.26B | 10.27 | 20.68% | 4.20% | 25.21% | 103.93% |
| HK:1666 | 64Neutral | HKD 3.82B | 10.78 | 4.19% | 6.93% | -13.93% | -25.30% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0570 | 53Neutral | HKD 5.89B | -4.81 | -4.98% | 0.30% | -15.80% | -298.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1666 | Tong Ren Tang Technologies Co Class H | 2.98 | -1.44 | -32.56% | |
| HK:3613 | Beijing Tong Ren Tang Chinese Medicine Co | 5.65 | -2.58 | -31.38% | |
| HK:0570 | China Traditional Chinese Medicine Holdings Co | 1.17 | -1.16 | -49.79% | |
| HK:1093 | CSPC Pharmaceutical Group | 7.87 | 0.50 | 6.75% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.48 | 0.25 | 11.09% |
Tong Ren Tang Technologies Co Corporate Events
Tong Ren Tang Technologies Posts RMB3.76 Billion Revenue in First Nine Months of 2026
Tong Ren Tang Technologies Co. Ltd. reported unaudited operating revenue of about RMB3,759.55 million and operating costs of roughly RMB2,337.57 million for the nine months ended 30 September 2026, resulting in net profit attributable to shareholders...
Tong Ren Tang Technologies Wins Macao Approval for Six Proprietary Chinese Medicines
Tong Ren Tang Technologies’ Macao subsidiary, Beijing Tong Ren Tang (Macau) Company Limited, has received Certificates of Registration for six proprietary Chinese medicines from the Chinese Medicine Council of Macao. The approvals cover Shilint...
Tong Ren Tang Technologies Wins Hong Kong Approval for New Chinese Medicine
Tong Ren Tang Technologies has announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine, has received a Certificate of Registration of Proprietary Chinese Medicine in Hong Kong for its product Dingzhi Wan 【Tong Ren Tang】. T...
Tong Ren Tang Technologies’ First-Half Profit Drops as Revenue Slides, Interim Dividend Scrapped
Tong Ren Tang Technologies reported a sharp decline in interim results for the six months ended 30 June 2026, with revenue falling 19.10% year on year to RMB3.02 billion and gross profit dropping accordingly. Profit attributable to shareholders sank...
Tong Ren Tang Technologies Signs New E-Commerce Deal With Connected Affiliate
Tong Ren Tang Technologies Co has signed a new e-commerce service cooperation framework agreement with affiliated company Tong Ren Tang Shuzi Technology, effective from 28 August 2026 to 31 December 2028. The deal aims to support the promotion and sa...
Tong Ren Tang Technologies Wins Hong Kong Approval for New Chinese Medicine
Tong Ren Tang Technologies Co. Ltd. announced that its Hong Kong subsidiary, Beijing Tong Ren Tang Chinese Medicine, has received a Certificate of Registration of Proprietary Chinese Medicine from the Chinese Medicine Council of Hong Kong. The approv...
Tong Ren Tang Technologies Sets Board Meeting to Review 2026 Interim Results
Tong Ren Tang Technologies Co. Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the unaudited consolidated interim results for the six months ended 30 June 2026. The board will also consider the potential declaration of an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026